Table 1 Different sources for human stem cell-derived insulin-producing cells
From: Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration
Cell of origin | Differentiation protocol | Time required for differentiation (days) | Differentiation product | Clinical trial | Site of transplantation | Encapsulation | Immunosuppression |
|---|---|---|---|---|---|---|---|
Embryonic stem cells | 14 | Pancreatic progenitor | Yes [19] NTC: 02239354 | Subcutaneous | Yes (VC-01) | No | |
Pluripotent stem cells | 14 | Pancreatic progenitor | Subcutaneous | Yes (VC-02) | Yes | ||
Pluripotent stem cells | 30–36 | Insulin-producing cells (VX-880) | Yes* | Intraportal | No | Yes | |
Mesenchymal stromal/stem cells | 10–21 | Insulin-producing cells | Under the renal capsule | No | No |